Advanced Tumors Clinical Trial
Official title:
Phase I Clinical Trial to Evaluate Safety, Tolerance and Pharmacokinetics of Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1) in Patients With Advanced Solid Tumors
The main purpose of this study was to evaluate the safety and tolerability of CDP1 in patients with advanced solid tumor, to explore dose limited toxicity (DLT), and to determine the recommended dose (RP2D) for phase II clinical trials.
OBJECTIVES:
Primary:
To evaluate the safety and tolerability of CDP1 in patients with advanced solid tumor, to
explore the dose limited toxicity (DLT), and to determine the recommended dose (RP2D) for
phase II clinical trial.
Secondary:
To evaluate the pharmacokinetics of CDP1 in patients with advanced solid tumor.
To evaluate the immunogenicity of CDP1 in patients with advanced solid tumor.
To evaluate the initial efficacy of CDP1 in patients with advanced solid tumor.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06314087 -
iTAPVR Study - Phase II Randomized Study
|
Phase 2 | |
| Recruiting |
NCT05390528 -
A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma
|
Phase 1/Phase 2 | |
| Completed |
NCT02419417 -
Study of BMS-986158 in Subjects With Select Advanced Cancers
|
Phase 1/Phase 2 | |
| Completed |
NCT04808453 -
Phase I Study of CPI-300 in Patients With Advanced Tumors
|
Phase 1 | |
| Recruiting |
NCT05799183 -
A SHR-1210 BE Study on Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT05429008 -
A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm
|
Phase 1 | |
| Terminated |
NCT04198818 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06245122 -
A Study of CS23546 in Subjects With Advanced Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT05213767 -
Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05068856 -
A Study of HRS2543 in Patients With Advanced Tumors
|
Phase 1 | |
| Completed |
NCT03781362 -
Study of CPI-100 in Patients With Advanced Tumors
|
Phase 1 | |
| Recruiting |
NCT03908814 -
Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05061628 -
The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor
|
Phase 1 | |
| Recruiting |
NCT05867771 -
A Study of PM1022 in Patients With Advanced Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03444714 -
Phase I Study of RiMO-301 With Radiation in Advanced Tumors
|
Phase 1 |